中文摘要：

目的：观察中药糖肾清1号对糖尿病肾病肾组织局部AngⅡ及TGFβ1 mRNA转录表达及蛋白表达水平的影响。方法：建立糖尿病肾病大鼠模型,设空白组、模型组、阳性药对照组（卡托普利24 mg.kg-1.d-1）、糖肾清1号甲、乙、丙、丁的高、中、低剂量治疗组（甲组给药糖肾清1号有效成分A,高剂量组94 mg.kg-1.d-1,中剂量组47 mg.kg-1.d-1,低剂量组23.5mg.kg-1.d-1。乙组给药糖肾清1号有效成分B,高剂量组94 mg.kg-1.d-1,中剂量组47 mg.kg-1.d-1,低剂量组23.5 mg.kg-1.d-1。丙组用药为1/2A与1/2B配成,高剂量组94 mg.kg-1.d-1,中剂量组47 mg.kg-1.d-1,低剂量组23.5 mg.kg-1.d-1。丁组为糖肾清1号生药制剂,高剂量组用药为195 mg.kg-1.d-1,中剂量为97.5 mg.kg-1.d-1,低剂量组48.75 mg.kg-1.d-1）,每组10只。分别采用RT-PCR,Western blot,ELISA等方法检测大鼠AngⅡ,TGF-β1 mRNA转录及蛋白表达水平,进行组织形态学观测。结果：糖肾清1号呈量效依赖性下调AngⅡ,TGF-β1 mRNA转录和蛋白表达（P〈0.01或0.05）,减少细胞外基质的沉积（P〈0.05）。结论：糖肾清1号可通过调控AngⅡ,TGF-β1 mRNA转录和蛋白表达,抑制肾组织纤维化的发生发展。

英文摘要：

Objective：To observe the effect of Tangshenqing No.1 on the transcription and expression of AngⅡ and TGFβ1 in the renal issue.Method： One hundred and forty-six rats were divided into control group（six rats）,model group（10 rats）,active-drug controlled group（10 rats）,and four treatment groups by Tangshengqing No.1,each designed as low-dose,mid-dose and high-dose groups（10 rats/group）.AngⅡ and TGF-β1 were tested by RT-PCR,Western blot,immunohistochemistry and pathomorphology.Result： Rats in treatment groups showed a significant down-regulated expression of mRNA and protein（P〈0.01 or P〈0.05）;ECM sediment was also decreased（P〈0.05）.Conclusion：Tangshenqing No.1 can curb the development of renal tissue fibrosis by regulate the mRNA transcription and protein expression of AngⅡ,TGF-β1.